Butylated Hydroxyanisole clinical trials
How each study uses Butylated Hydroxyanisole is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- BHA
- 3
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Carmell Therapeutics Corporation (3)
Related medicines
As reviewed, each with the page that says it.
- One of Antioxidants source
Studies
Open first, then newest update. How each study uses Butylated Hydroxyanisole is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle ArthrodesisWithdrawnPhase 2Carmell Therapeutics CorporationNCT06258499Written as BHA
- Multiregion BHA in Open Tibia FracturesWithdrawnPhase 2Carmell Therapeutics CorporationNCT04056429Written as BHA
- Bone Healing Accelerant Versus Standard of Care for Open Tibia FracturesWithdrawnPhase 3Carmell Therapeutics CorporationNCT03826784Written as BHA